IL93360A - Bactericidal/permeability increasing protein or biologically active analogs thereof and pharmaceutical compositions containing them - Google Patents

Bactericidal/permeability increasing protein or biologically active analogs thereof and pharmaceutical compositions containing them

Info

Publication number
IL93360A
IL93360A IL93360A IL9336090A IL93360A IL 93360 A IL93360 A IL 93360A IL 93360 A IL93360 A IL 93360A IL 9336090 A IL9336090 A IL 9336090A IL 93360 A IL93360 A IL 93360A
Authority
IL
Israel
Prior art keywords
bactericidal
biologically active
pharmaceutical compositions
compositions containing
increasing protein
Prior art date
Application number
IL93360A
Other languages
English (en)
Original Assignee
Incyte Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals filed Critical Incyte Pharmaceuticals
Publication of IL93360A publication Critical patent/IL93360A/xx

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742Bactericidal/Permeability-increasing protein [BPI]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02BINTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00Other engines
    • F02B75/02Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL93360A 1989-02-14 1990-02-12 Bactericidal/permeability increasing protein or biologically active analogs thereof and pharmaceutical compositions containing them IL93360A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31084289A 1989-02-14 1989-02-14
US07/468,696 US5089274A (en) 1989-02-14 1990-01-22 Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders

Publications (1)

Publication Number Publication Date
IL93360A true IL93360A (en) 1997-04-15

Family

ID=26977616

Family Applications (1)

Application Number Title Priority Date Filing Date
IL93360A IL93360A (en) 1989-02-14 1990-02-12 Bactericidal/permeability increasing protein or biologically active analogs thereof and pharmaceutical compositions containing them

Country Status (11)

Country Link
US (1) US5089274A (de)
EP (3) EP1384485A1 (de)
JP (1) JP2966923B2 (de)
KR (1) KR0160133B1 (de)
AT (2) ATE169820T1 (de)
AU (1) AU647734B2 (de)
CA (1) CA2048619C (de)
DE (2) DE69034096T2 (de)
ES (2) ES2205111T3 (de)
IL (1) IL93360A (de)
WO (1) WO1990009183A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6132775A (en) * 1987-08-11 2000-10-17 New York University Therapeutic uses of biologically active bactericidal/permeability-increasing protein fragments
EP1659132A1 (de) * 1987-08-11 2006-05-24 New York University BPI Fragmente
US5594113A (en) * 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
WO1994025476A1 (en) * 1993-04-30 1994-11-10 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US6265187B1 (en) 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US6093801A (en) * 1989-02-14 2000-07-25 Incyte Pharmaceuticals, Inc. Recombinant analogs of bactericidal/permeability increasing protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
US5489676A (en) * 1990-03-30 1996-02-06 Elsbach; Peter Polypeptides that potentiate bactericidal/permeability-increasing protein and methods for treating bacterial infections
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
EP0586573B1 (de) * 1991-05-16 2001-12-19 Associates Of Cape Cod, Inc. Endotoxinbindendes und -neutralisierendes protein und verwendungen dafür
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト ファーマシューティカルズ,インコーポレイテッド 新規な形態のリポ糖結合性タンパク質(lbp)
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性/浸透性増大タンパク質(Bactericidal/Permeability Increasing protein:BPI)及び界面活性剤を含有する医薬組成物
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
US6214789B1 (en) * 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1995000641A1 (en) 1993-06-17 1995-01-05 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
DE69430823T2 (de) * 1993-09-22 2003-02-20 Xoma Technology Ltd., Berkeley Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
PT754050E (pt) * 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
DE69526216T2 (de) * 1994-01-14 2002-11-14 Xoma Technology Ltd., Berkeley Antifungaleverfahren und mitteln
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
PL316935A1 (en) * 1994-04-21 1997-02-17 Novo Nordisk As Heparin bonding protein for treating septicaemia and method of obtaining such protein
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US5610075A (en) * 1995-01-17 1997-03-11 Stahl-Rees; Marianne Competitive electrochemiluminescence assays for endotoxins using a ruthenium label
US5939390A (en) * 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
JP2000510845A (ja) * 1996-05-10 2000-08-22 ゾーマ コーポレイション ヒト髄膜炎菌血症のためのbpiタンパク質産物の治療用途
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
JP2000511190A (ja) * 1996-05-23 2000-08-29 ゾーマ コーポレイション 外傷に起因する出血に見舞われたヒトにおけるbpiタンパク質産物の治療用途
EP0939766A2 (de) 1996-05-24 1999-09-08 The Regents Of The University Of Minnesota Synthese von löslichen beta-sheet bildenden peptiden
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
IL142248A0 (en) * 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
WO2003070751A2 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
IL262930B2 (en) 2016-05-27 2023-11-01 Exoxemis Inc Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006279A1 (en) * 1985-04-30 1986-11-06 Scripps Clinic And Research Foundation Acute phase protein modulating endotoxic activity of lipopolysaccharides, compositions and methods
US5108131A (en) * 1986-10-07 1992-04-28 Mainframe Data Limited Method of controlling transmission of defects
US5126257A (en) * 1986-11-26 1992-06-30 Cornell Research Foundation Antimicrobial proteins, compositions containing same and uses thereof
EP1659132A1 (de) * 1987-08-11 2006-05-24 New York University BPI Fragmente
GB8815978D0 (en) * 1988-07-05 1988-08-10 British Telecomm Method & apparatus for encoding decoding & transmitting data in compressed form

Also Published As

Publication number Publication date
JP2966923B2 (ja) 1999-10-25
EP0460058B1 (de) 1998-08-19
CA2048619C (en) 2001-02-13
KR0160133B1 (en) 1998-12-01
ATE169820T1 (de) 1998-09-15
AU5170690A (en) 1990-09-05
WO1990009183A1 (en) 1990-08-23
EP0841064A1 (de) 1998-05-13
US5089274A (en) 1992-02-18
DE69034096D1 (de) 2003-09-18
AU647734B2 (en) 1994-03-31
EP1384485A1 (de) 2004-01-28
CA2048619A1 (en) 1990-08-15
DE69032579T2 (de) 1999-02-11
EP0841064B1 (de) 2003-08-13
JPH04506510A (ja) 1992-11-12
ATE246933T1 (de) 2003-08-15
DE69034096T2 (de) 2004-06-17
ES2205111T3 (es) 2004-05-01
DE69032579D1 (de) 1998-09-24
ES2122958T3 (es) 1999-01-01
EP0460058A4 (en) 1992-02-12
EP0460058A1 (de) 1991-12-11

Similar Documents

Publication Publication Date Title
IL93360A (en) Bactericidal/permeability increasing protein or biologically active analogs thereof and pharmaceutical compositions containing them
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
JO1502B1 (en) New pharmacy vehicles
EG18379A (en) Novel pharmacological compounds
FI884384A0 (fi) Yliannostuksen estolla varustettu sumutinpakkaus fysiologisesti aktiivisten aineiden itseannostelemiseksi
MX9206577A (es) COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES
PT76314A (en) Process for the preparation of biologically active polysaccharide concentrates and of pharmaceutical and cosmetic compositions containing them
PL328003A1 (en) Modulation of cytokin th 1/th 2 expression by means of ribavirin and ribavirin analoques in t lymphocytes
FI886019A7 (fi) Laastari vaikuttavien aineiden valvotusti jakamiseksi iholle
DE3681144D1 (de) Verwendung biologisch aktiver copolymere zur herstellung eines arzneimittels zur stimulierung des wachstums von tieren.
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
ZA773259B (en) Improvements in or relating to methods for reducing the doses of biologically active substances while maintaining the biological effects
IL95875A0 (en) Illudin analogs,pharmaceutical compositions containing the same and methods for the use thereof
GB2177919B (en) Synergistic biologically active substances
IL74827A (en) Peptides active as gnrh antagonists and pharmaceutical compositions containing them
AU3691589A (en) Preparation containing active ingredients of plant origin for use in cosmetics
ZA867839B (en) Biologically active derivatives of human ypsilon-interferon
UA27048C2 (uk) Лікарський препарат імуhокоригуючої дії hа осhові клітиhhої суспеhзії, спосіб лікуваhhя цукрового діабету з використаhhям цього препарату
GEP19970992B (en) Implant for Parenteral Introducing with Controlled Speed
FR2753371B1 (fr) Utilisation d'un extrait de la plante terminalia catappa et compositions cosmetique dermatologique et pharmaceutique comportant un tel extrait
ES8707553A1 (es) Procedimiento para la obtencion de un peptido.
IL75186A0 (en) Biologically active agents containing substituted isoxazolidines,certain such novel compounds and their preparation
ATE24716T1 (de) Lenkotrien-antagonisten.
GB2180746B (en) Compositions for administering biologically active peptides via mucous membranes
HUT41818A (en) Process for preparing peptides for growth stimulation and pharmaceutical compositions containing such compounds as active substances

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
RH1 Patent not in force